UA97505C2 - ПРИМЕНЕНИЕ N-[2-(2,1,3-БЕНЗОТИАДИАЗОЛ-5-ИЛАМИНО)-6-(2,6-ДИХЛОРФЕНИЛ)ПИРИДО[2,3-d]ПИРИМИДИН-7-ИЛ]-N'-(1,1-ДИМЕТИЛЭТИЛ)-МОЧЕВИНЫ ДЛЯ ЛЕЧЕНИЯ МИЕЛОЛЕЙКОЗОВ - Google Patents

ПРИМЕНЕНИЕ N-[2-(2,1,3-БЕНЗОТИАДИАЗОЛ-5-ИЛАМИНО)-6-(2,6-ДИХЛОРФЕНИЛ)ПИРИДО[2,3-d]ПИРИМИДИН-7-ИЛ]-N'-(1,1-ДИМЕТИЛЭТИЛ)-МОЧЕВИНЫ ДЛЯ ЛЕЧЕНИЯ МИЕЛОЛЕЙКОЗОВ

Info

Publication number
UA97505C2
UA97505C2 UAA200907941A UAA200907941A UA97505C2 UA 97505 C2 UA97505 C2 UA 97505C2 UA A200907941 A UAA200907941 A UA A200907941A UA A200907941 A UAA200907941 A UA A200907941A UA 97505 C2 UA97505 C2 UA 97505C2
Authority
UA
Ukraine
Prior art keywords
benzothiadiazol
pyrido
ylamino
dimethylethyl
pyrimidin
Prior art date
Application number
UAA200907941A
Other languages
English (en)
Ukrainian (uk)
Inventor
Бернар Буррі
П'єр Казелла
Original Assignee
Санофи-Авентис
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38268928&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UA97505(C2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Санофи-Авентис filed Critical Санофи-Авентис
Publication of UA97505C2 publication Critical patent/UA97505C2/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

Изобретение относится к области медицины и касается применения соединения N-[2-(2,1,3-бензотиадиазол-5-иламино)-6-(2,6-дихлорфенил)пиридо[2,3-d]пиримидин-7-ил]-N'-(1,1-диметилэтил)-мочевины или его гидрата, соли или сольвата для получения лекарственного средства, предназначенного для лечения миелолейкозов.
UAA200907941A 2006-12-28 2007-12-27 ПРИМЕНЕНИЕ N-[2-(2,1,3-БЕНЗОТИАДИАЗОЛ-5-ИЛАМИНО)-6-(2,6-ДИХЛОРФЕНИЛ)ПИРИДО[2,3-d]ПИРИМИДИН-7-ИЛ]-N'-(1,1-ДИМЕТИЛЭТИЛ)-МОЧЕВИНЫ ДЛЯ ЛЕЧЕНИЯ МИЕЛОЛЕЙКОЗОВ UA97505C2 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0611492A FR2910813B1 (fr) 2006-12-28 2006-12-28 Nouvelle utilisation therapeutique pour le traitement des leucemies
PCT/FR2007/002171 WO2008102075A2 (fr) 2006-12-28 2007-12-27 Nouvelle utilisation therapeutique pour le traitement des leucemies

Publications (1)

Publication Number Publication Date
UA97505C2 true UA97505C2 (ru) 2012-02-27

Family

ID=38268928

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA200907941A UA97505C2 (ru) 2006-12-28 2007-12-27 ПРИМЕНЕНИЕ N-[2-(2,1,3-БЕНЗОТИАДИАЗОЛ-5-ИЛАМИНО)-6-(2,6-ДИХЛОРФЕНИЛ)ПИРИДО[2,3-d]ПИРИМИДИН-7-ИЛ]-N'-(1,1-ДИМЕТИЛЭТИЛ)-МОЧЕВИНЫ ДЛЯ ЛЕЧЕНИЯ МИЕЛОЛЕЙКОЗОВ

Country Status (40)

Country Link
US (1) US8236811B2 (ru)
EP (1) EP2107906B1 (ru)
JP (1) JP5317987B2 (ru)
KR (1) KR101458233B1 (ru)
CN (1) CN101568338B (ru)
AR (1) AR064550A1 (ru)
AT (1) ATE534392T1 (ru)
AU (1) AU2007347370B2 (ru)
BR (1) BRPI0720963A2 (ru)
CA (1) CA2672716C (ru)
CL (1) CL2007003846A1 (ru)
CO (1) CO6190610A2 (ru)
CR (1) CR10881A (ru)
CY (1) CY1112443T1 (ru)
DK (1) DK2107906T3 (ru)
EA (1) EA016873B1 (ru)
EC (1) ECSP099449A (ru)
ES (1) ES2377843T3 (ru)
FR (1) FR2910813B1 (ru)
GT (1) GT200900168A (ru)
HK (1) HK1138189A1 (ru)
HR (1) HRP20120170T1 (ru)
JO (1) JO2748B1 (ru)
MA (1) MA31100B1 (ru)
MX (1) MX2009007054A (ru)
MY (1) MY148515A (ru)
NI (1) NI200900129A (ru)
NO (1) NO20092496L (ru)
NZ (1) NZ577991A (ru)
PE (1) PE20081548A1 (ru)
PL (1) PL2107906T3 (ru)
PT (1) PT2107906E (ru)
RS (1) RS52162B (ru)
SI (1) SI2107906T1 (ru)
SV (1) SV2009003315A (ru)
TN (1) TN2009000234A1 (ru)
TW (1) TWI433678B (ru)
UA (1) UA97505C2 (ru)
WO (1) WO2008102075A2 (ru)
ZA (1) ZA200904478B (ru)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2948568B1 (fr) 2009-07-30 2012-08-24 Sanofi Aventis Formulation pharmaceutique
EP2638911A1 (en) 2012-03-14 2013-09-18 Sanofi Novel combinations for treating acute myeloid leukaemia or chronic myeloid leukaemia
AR098716A1 (es) * 2013-12-13 2016-06-08 Novartis Ag Formas de dosificación farmacéuticas
US20230136218A1 (en) * 2019-09-23 2023-05-04 President And Fellows Of Harvard College Methods and compositions for treating acute myeloid leukemia

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1171218A (en) 1967-11-09 1969-11-19 Parke Davis & Co New Heterocyclic Amine Compounds and Methods for their Production
EP0790997B1 (en) 1994-11-14 2000-03-22 Warner-Lambert Company 6-ARYL PYRIDO[2,3-d]PYRIMIDINES AND NAPHTHYRIDINES FOR INHIBITING PROTEIN TYROSINE KINASE MEDIATED CELLULAR PROLIFERATION
IL115256A0 (en) 1994-11-14 1995-12-31 Warner Lambert Co 6-Aryl pyrido (2,3-d) pyrimidines and naphthyridines and their use
US5620981A (en) 1995-05-03 1997-04-15 Warner-Lambert Company Pyrido [2,3-D]pyrimidines for inhibiting protein tyrosine kinase mediated cellular proliferation
IL117923A (en) 1995-05-03 2000-06-01 Warner Lambert Co Anti-cancer pharmaceutical compositions containing polysubstituted pyrido¬2,3-d¾pyrimidine derivatives and certain such novel compounds
AU7315700A (en) 1999-09-20 2001-04-24 Takeda Chemical Industries Ltd. Melanin concentrating hormone antagonist
AP2002002586A0 (en) 2000-01-25 2002-09-30 Warner Lambert Co Pyrido[2,3-d] pyrimidine-2,7-diamine kinase inhibitors.
IL151480A0 (en) 2000-03-06 2003-04-10 Warner Lambert Co 5-alkylpyrido[2,3-d] pyrimidines tyrosine kinase inhibitors
EP1307450B1 (en) 2000-08-04 2008-09-17 Warner-Lambert Company LLC 2-(4-Pyridyl)amino-6-dialkoxyphenyl-pyrido(2,3-d)pyrimidin-7-ones
US20030105115A1 (en) * 2001-06-21 2003-06-05 Metcalf Chester A. Novel pyridopyrimidines and uses thereof
WO2004063195A1 (en) 2003-01-03 2004-07-29 Sloan-Kettering Institute For Cancer Research Pyridopyrimidine kinase inhibitors
TW200502236A (en) 2003-03-28 2005-01-16 Hoffmann La Roche Novel pyrido[2,3-d]pyrimidin-7-carboxylic acid derivatives, their manufacture and use as pharmaceutical agents
WO2005105097A2 (en) 2004-04-28 2005-11-10 Gpc Biotech Ag Pyridopyrimidines for treating inflammatory and other diseases
FR2873118B1 (fr) 2004-07-15 2007-11-23 Sanofi Synthelabo Derives de pyrido-pyrimidine, leur application en therapeutique
UY29017A1 (es) 2004-07-16 2006-02-24 Boehringer Ingelheim Int Inhibidores de polimerasa viral
FR2887882B1 (fr) * 2005-07-01 2007-09-07 Sanofi Aventis Sa Derives de pyrido[2,3-d] pyrimidine, leur preparation, leur application en therapeutique
FR2896246B1 (fr) 2006-01-13 2008-08-15 Sanofi Aventis Sa Derives de pyrido-pyrimidone, leur preparation, leur application en therapeutique.

Also Published As

Publication number Publication date
ZA200904478B (en) 2010-08-25
CA2672716C (fr) 2013-05-28
MA31100B1 (fr) 2010-01-04
EP2107906B1 (fr) 2011-11-23
KR101458233B1 (ko) 2014-11-04
EA200970639A1 (ru) 2010-04-30
PL2107906T3 (pl) 2012-04-30
TN2009000234A1 (fr) 2010-10-18
CN101568338A (zh) 2009-10-28
EA016873B1 (ru) 2012-08-30
JO2748B1 (en) 2014-03-15
SI2107906T1 (sl) 2012-03-30
CY1112443T1 (el) 2015-12-09
NI200900129A (es) 2011-12-13
ES2377843T3 (es) 2012-04-02
FR2910813B1 (fr) 2009-02-06
TWI433678B (zh) 2014-04-11
GT200900168A (es) 2010-03-19
WO2008102075A2 (fr) 2008-08-28
DK2107906T3 (da) 2012-03-19
MY148515A (en) 2013-04-30
HK1138189A1 (en) 2010-08-20
CA2672716A1 (fr) 2008-08-28
FR2910813A1 (fr) 2008-07-04
NZ577991A (en) 2012-01-12
TW200833343A (en) 2008-08-16
MX2009007054A (es) 2009-08-12
AU2007347370B2 (en) 2013-05-23
AR064550A1 (es) 2009-04-08
HRP20120170T1 (hr) 2012-03-31
CO6190610A2 (es) 2010-08-19
PE20081548A1 (es) 2009-01-04
EP2107906A2 (fr) 2009-10-14
ATE534392T1 (de) 2011-12-15
US8236811B2 (en) 2012-08-07
JP2010514743A (ja) 2010-05-06
CR10881A (es) 2009-08-12
CL2007003846A1 (es) 2009-01-23
WO2008102075A3 (fr) 2008-12-11
BRPI0720963A2 (pt) 2014-03-18
NO20092496L (no) 2009-07-23
CN101568338B (zh) 2011-11-23
RS52162B (en) 2012-08-31
KR20090103899A (ko) 2009-10-01
SV2009003315A (es) 2010-02-05
PT2107906E (pt) 2012-03-05
US20090298790A1 (en) 2009-12-03
JP5317987B2 (ja) 2013-10-16
ECSP099449A (es) 2009-07-31
AU2007347370A1 (en) 2008-08-28

Similar Documents

Publication Publication Date Title
TW200621716A (en) Novel compounds
TW200611701A (en) Novel compounds
TW200500344A (en) Novel compounds
IL185546A0 (en) N - (n - sulfonylaminomethyl) cyclopropanecarboxamide derivatives useful for the treatment of pain
WO2006055561A3 (en) Stereoisomerically enriched 3-aminocarbonyl bicycloheptene pyrimidinediamine compounds and their uses
UA85559C2 (en) Aminobenzophenone compounds
TW200800999A (en) Novel compounds
TN2012000062A1 (en) Jak 2 inhibitors and their use for the treatment of myeloproliferative deseases and cancer
TW200508214A (en) Novel compounds
ZA200604114B (en) Use of substituted 2-aminotetralines for the preventative treatment of parkinson's disease
WO2006110298A3 (en) 8-alkyl/aryl-4-aryl-2-n- (alkylamino)-n'-substituted-n'-cyanoguanidino-8h-pyrido[2,3-d]pyrimidin-7-one compounds and use thereof
UA90698C2 (en) Triazole substituted aminobenzophenone compounds
TW200744567A (en) Phenylethylamine analogs and their use for treating glaucoma
WO2007120333A3 (en) Tetracyclic kinase inhibitors
TNSN07440A1 (en) Derivatives of pyrido [2,3 -d] pyrimidine, the preparation thereof, and the therapeutic application of the same
HK1093729A1 (en) Substituted quinolones
TW200726763A (en) Novel compound
TW200700411A (en) Heterocyclylamide-substituted imidazoles
WO2006130726A3 (en) Use of ladostigil for the treatment of multiple sclerosis
TW200734324A (en) Therapeutic agents
UA97505C2 (ru) ПРИМЕНЕНИЕ N-[2-(2,1,3-БЕНЗОТИАДИАЗОЛ-5-ИЛАМИНО)-6-(2,6-ДИХЛОРФЕНИЛ)ПИРИДО[2,3-d]ПИРИМИДИН-7-ИЛ]-N'-(1,1-ДИМЕТИЛЭТИЛ)-МОЧЕВИНЫ ДЛЯ ЛЕЧЕНИЯ МИЕЛОЛЕЙКОЗОВ
TW200728300A (en) Therapeutic agents
HK1112228A1 (en) Substituted azachinzolines having an antiviral action
MX2008001428A (es) Compuestos de imidazolil-pirimidina para uso en el tratamiento de trastornos proliferativos.
ZA201000581B (en) 1,2,3,4-tetrahydropyrrolo[1,2-a]pyrazine-6-carboxamide and 2,3,4,5-tetrahydropyrrolo[1,2-a][1,4]-diazepine-7-carboxamide derivatives,preparation and therapeutic use thereof